Bio-Techne price target lowered to $82 from $85 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Bio-Techne to $82 from $85 and keeps a Buy rating on the shares. The firm’s survey across U.S. academic and clinical research laboratories suggests a softening of the academic and government end market in Q1. It dropped the price target to reflect lower revenue estimates. Spending is softening across major categories with diagnostics and consumables categories more buoyant than instrument and capex-sensitive spend, the analyst tells investors in a research note.